CNBC.com's Lawrence Delevingne discusses Herbalife's 49 percent fall in 2013.» Read More
Herbalife shares are attractive despite high-profile short interest in the stock, Kerrisdale Capital's Sahm Adrangi says.
Sahm Adrangi, Kerrisdale Capital Management, explains why he took a long position on Herbalife when the stock was trading at $26.
Herbalife's annual growth rate makes the stock attractive at its current level, Kerrisdale Capital Management Founder Sahm Adrangi says.
Stocks extended their gains in the final hour of trading to close near session highs Thursday, with all key S&P sectors finishing in positive territory, but volume was light amid caution ahead of next week's flurry of earnings report.
Herbalife ratcheted up its defense against activist investor Bill Ackman, with CNBC's Brian Shactman.
Herbalife is fighting back against Bill Ackman with an investor day today, reports CNBC's Herb Greenberg.
"Let's be honest with each other, here," Herbalife CEO Michael Johnson told CNBC Thursday. "He's going to donate all of his profits to charity? He's got participants in that(hedge) fund...Who knows where it's really going?"
Bill Ackman says "we will respond to every issue raised by Herblife." CNBC's Herb Greenberg reports.
Herablife will file an update on Q4 performance next week. CNBC's Herb Greenberg discusses his interview with Herbalife CEO Michael Johnson.
Michael Johnson, Herbalife CEO, discusses his company's business model and explains how distributors receive compensation, with CNBC's Kate Kelly.
Two of the richest and most prominent hedge fund managers in Manhattan are locked in a battle over nutritional supplement provider Herbalife. The New York Times reports.
CNBC's Herb Greenberg explains why the drama with Herbalife is far from over. And CNBC's Kate Kelly provides an update on the company from the analyst meeting.
Herbalife President Des Walsh told CNBC on Thursday that hedge fund manager Bill Ackman's allegations are completely false.
The "Squawk on the Street" crew discusses the dispute between two hedge fund titans over the reputation of Herbalife.
AIG decided not to join former chief Hank Greenberg in his lawsuit against the government. David Boies, Boies, Schiller & Flexner chairman, discusses the merits of the case and why his client is not backing down.
Des Walsh, Herbalife president, responds to claims made by activist investor Bill Ackman that the company is a "pyramid scheme."
Some of the names on the move ahead of the open.
SEC's Director of Enforcement, Robert Khuzami responds to rumor of Herbalife inquiry.
Bank of America was the biggest gainer in the Dow in 2012, and the Fast Money traders discuss how to play the stock now; and everything you need to know about Herbalife's stock, with CNBC's Herb Greenberg.
Stocks ended higher in thin trading Wednesday, after Dow component Alcoa kicked off the fourth-quarter earnings season on a positive note.